Selective Development of Myogenic Mesenchymal Cells from Human Embryonic and Induced Pluripotent Stem Cells

Tomonari Awaya, Takeo Kato, Yuta Mizuno, Hsi Chang, Akira Niwa, Katsutsugu Umeda, Tatsutoshi Nakahata, Toshio Heike

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells are promising sources for the cell therapy of muscle diseases and can serve as powerful experimental tools for skeletal muscle research, provided an effective method to induce skeletal muscle cells is established. However, the current methods for myogenic differentiation from human ES cells are still inefficient for clinical use, while myogenic differentiation from human iPS cells remains to be accomplished. Here, we aimed to establish a practical differentiation method to induce skeletal myogenesis from both human ES and iPS cells. To accomplish this goal, we developed a novel stepwise culture method for the selective expansion of mesenchymal cells from cell aggregations called embryoid bodies. These mesenchymal cells, which were obtained by dissociation and re-cultivation of embryoid bodies, uniformly expressed CD56 and the mesenchymal markers CD73, CD105, CD166, and CD29, and finally differentiated into mature myotubes in vitro. Furthermore, these myogenic mesenchymal cells exhibited stable long-term engraftment in injured muscles of immunodeficient mice in vivo and were reactivated upon subsequent muscle damage, increasing in number to reconstruct damaged muscles. Our simple differentiation system facilitates further utilization of ES and iPS cells in both developmental and pathological muscle research and in serving as a practical donor source for cell therapy of muscle diseases.

Original languageEnglish
Article numbere51638
JournalPLoS One
Volume7
Issue number12
DOIs
Publication statusPublished - Dec 7 2012
Externally publishedYes

Fingerprint

Induced Pluripotent Stem Cells
Stem cells
Muscle
Muscles
Embryoid Bodies
muscles
muscular diseases
embryonic stem cells
cells
Cell- and Tissue-Based Therapy
skeletal muscle
Skeletal Muscle
Cell Aggregation
therapeutics
stems
Muscle Development
muscle development
Skeletal Muscle Fibers
methodology
Research

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Selective Development of Myogenic Mesenchymal Cells from Human Embryonic and Induced Pluripotent Stem Cells. / Awaya, Tomonari; Kato, Takeo; Mizuno, Yuta; Chang, Hsi; Niwa, Akira; Umeda, Katsutsugu; Nakahata, Tatsutoshi; Heike, Toshio.

In: PLoS One, Vol. 7, No. 12, e51638, 07.12.2012.

Research output: Contribution to journalArticle

Awaya, Tomonari ; Kato, Takeo ; Mizuno, Yuta ; Chang, Hsi ; Niwa, Akira ; Umeda, Katsutsugu ; Nakahata, Tatsutoshi ; Heike, Toshio. / Selective Development of Myogenic Mesenchymal Cells from Human Embryonic and Induced Pluripotent Stem Cells. In: PLoS One. 2012 ; Vol. 7, No. 12.
@article{b55e88547a5e43e2ad0019f4e28a03e8,
title = "Selective Development of Myogenic Mesenchymal Cells from Human Embryonic and Induced Pluripotent Stem Cells",
abstract = "Human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells are promising sources for the cell therapy of muscle diseases and can serve as powerful experimental tools for skeletal muscle research, provided an effective method to induce skeletal muscle cells is established. However, the current methods for myogenic differentiation from human ES cells are still inefficient for clinical use, while myogenic differentiation from human iPS cells remains to be accomplished. Here, we aimed to establish a practical differentiation method to induce skeletal myogenesis from both human ES and iPS cells. To accomplish this goal, we developed a novel stepwise culture method for the selective expansion of mesenchymal cells from cell aggregations called embryoid bodies. These mesenchymal cells, which were obtained by dissociation and re-cultivation of embryoid bodies, uniformly expressed CD56 and the mesenchymal markers CD73, CD105, CD166, and CD29, and finally differentiated into mature myotubes in vitro. Furthermore, these myogenic mesenchymal cells exhibited stable long-term engraftment in injured muscles of immunodeficient mice in vivo and were reactivated upon subsequent muscle damage, increasing in number to reconstruct damaged muscles. Our simple differentiation system facilitates further utilization of ES and iPS cells in both developmental and pathological muscle research and in serving as a practical donor source for cell therapy of muscle diseases.",
author = "Tomonari Awaya and Takeo Kato and Yuta Mizuno and Hsi Chang and Akira Niwa and Katsutsugu Umeda and Tatsutoshi Nakahata and Toshio Heike",
year = "2012",
month = "12",
day = "7",
doi = "10.1371/journal.pone.0051638",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Selective Development of Myogenic Mesenchymal Cells from Human Embryonic and Induced Pluripotent Stem Cells

AU - Awaya, Tomonari

AU - Kato, Takeo

AU - Mizuno, Yuta

AU - Chang, Hsi

AU - Niwa, Akira

AU - Umeda, Katsutsugu

AU - Nakahata, Tatsutoshi

AU - Heike, Toshio

PY - 2012/12/7

Y1 - 2012/12/7

N2 - Human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells are promising sources for the cell therapy of muscle diseases and can serve as powerful experimental tools for skeletal muscle research, provided an effective method to induce skeletal muscle cells is established. However, the current methods for myogenic differentiation from human ES cells are still inefficient for clinical use, while myogenic differentiation from human iPS cells remains to be accomplished. Here, we aimed to establish a practical differentiation method to induce skeletal myogenesis from both human ES and iPS cells. To accomplish this goal, we developed a novel stepwise culture method for the selective expansion of mesenchymal cells from cell aggregations called embryoid bodies. These mesenchymal cells, which were obtained by dissociation and re-cultivation of embryoid bodies, uniformly expressed CD56 and the mesenchymal markers CD73, CD105, CD166, and CD29, and finally differentiated into mature myotubes in vitro. Furthermore, these myogenic mesenchymal cells exhibited stable long-term engraftment in injured muscles of immunodeficient mice in vivo and were reactivated upon subsequent muscle damage, increasing in number to reconstruct damaged muscles. Our simple differentiation system facilitates further utilization of ES and iPS cells in both developmental and pathological muscle research and in serving as a practical donor source for cell therapy of muscle diseases.

AB - Human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells are promising sources for the cell therapy of muscle diseases and can serve as powerful experimental tools for skeletal muscle research, provided an effective method to induce skeletal muscle cells is established. However, the current methods for myogenic differentiation from human ES cells are still inefficient for clinical use, while myogenic differentiation from human iPS cells remains to be accomplished. Here, we aimed to establish a practical differentiation method to induce skeletal myogenesis from both human ES and iPS cells. To accomplish this goal, we developed a novel stepwise culture method for the selective expansion of mesenchymal cells from cell aggregations called embryoid bodies. These mesenchymal cells, which were obtained by dissociation and re-cultivation of embryoid bodies, uniformly expressed CD56 and the mesenchymal markers CD73, CD105, CD166, and CD29, and finally differentiated into mature myotubes in vitro. Furthermore, these myogenic mesenchymal cells exhibited stable long-term engraftment in injured muscles of immunodeficient mice in vivo and were reactivated upon subsequent muscle damage, increasing in number to reconstruct damaged muscles. Our simple differentiation system facilitates further utilization of ES and iPS cells in both developmental and pathological muscle research and in serving as a practical donor source for cell therapy of muscle diseases.

UR - http://www.scopus.com/inward/record.url?scp=84870890283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870890283&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0051638

DO - 10.1371/journal.pone.0051638

M3 - Article

C2 - 23236522

AN - SCOPUS:84870890283

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e51638

ER -